IN VITRO-IN VIVO BIO-EQUIVALENCE CORRELATION STUDY OF ATENOLOL, AND ITS BRANDS OF IMMEDIATE RELEASE TABLET UNDER BIO-WAIVER CONDITIONS

  • Ahmed EM College of Pharmacy, Department of Pharmaceutical Chemistry, Ribat National University, Khartoum, Sudan.
  • Ibrahim ME College of Pharmacy, Department of Pharmaceutical Chemistry, Ribat National University, Khartoum, Sudan.
  • Magbool FF Department of Pharmaceutical Chemistry, Omdurman Islamic University, Sudan. https://orcid.org/0000-0003-0411-4120

Abstract

Objective: The aim of present study is to examine the in vitro-in vivo correlation (IVIVC) of immediate release product. Atenolol 100mg and its brands of immediate release dosage forms. Atenolol is clearly classified into BCS class III, and could be evaluated under bio waiver conditions.


Methods: The in vitro parameters employed were hardness, weight uniformity, friability, disintegration time, absolute drug content, dissolution rate (in 0.1 N Hydrochloric acid, phosphate buffer and acetate buffer at 37ºC), and dissolution efficiencies were also analyzed. The in-vitro dissolution study was performed on the brands, according to FDA, USP  dissolution profile in three different PH (1.2), (4.5), and (6.8) at 37ºC, using the USP apparatus II. A non linear relation was established which is typical for immediate release formulation, of class III.


Results: All Atenolol brands released about 90% drug in PH (6.8), where about 87% in PH (4.5), reference drug released about 91% and test drug released about 87% in pH (1.2). Dissolution efficiency of  the entire brands differed by less than 10% from the innovator brand. According to MINITAM 14 statistical program, there was significant relationship between in vitro and in vivo data of reference Atenolol product.


Conclusion: By applying level A in vitro-in vivo correlation, study concluded that there is no linear correlation between percent of drug released and percent of drug absorbed, this may be due to uncontrollable permeability rate for class three Atenolol.


Peer Review History:


Received 20 September 2019;   Revised 16 December; Accepted 7 January, Available online 15 January 2020


UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency.


Received file


pdf3.JPG


Average Peer review marks at initial stage: 3.0/10


Average Peer review marks at publication stage: 7.0/10


Reviewer(s) detail:


Name: Dr. Hayriye Eda Şatana Kara  


Affiliation: Gazi University, Turkey


E-mail: eda@gazi.edu.tr


 


Name: Dr. Nicola Micale  


Affiliation: University of Messina, Italy


E-mail: nmicale@unime.it


 


Comments of reviewer(s):


pdf3.JPG


Similar Articles:


FAST DISSOLVING DRUG DELIVERY SYSTEMS: FORMULATION, PREPARATION TECHNIQUES AND EVALUATION


FAST DISSOLVING TABLETS: A PROMISING APPROACH FOR DRUG DELIVERY


DEVELOPMENT AND EVALUATION OF FAST DISSOLVING THIN FILMS OF ARIPIPRAZOLE


TABLET GRANULATION: CURRENT SCENARIO AND RECENT ADVANCES


 

Keywords: Bioavailability, bioequivalence, biopharmaceutical classification system, Bio-waiver correlation
Statistics
73 Views | 91 Downloads
How to Cite
EM, A., I. ME, and M. FF. “IN VITRO-IN VIVO BIO-EQUIVALENCE CORRELATION STUDY OF ATENOLOL, AND ITS BRANDS OF IMMEDIATE RELEASE TABLET UNDER BIO-WAIVER CONDITIONS”. Universal Journal of Pharmaceutical Research, Vol. 4, no. 6, Jan. 2020, doi:https://doi.org/10.22270/ujpr.v4i6.332.
Section
Research Articles